Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

OBJECTIVES: Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking. This trial assessed the preferential Janus kinase 1 (JAK1) inhibitor filgoti...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Matthew, Chaichian, Yashaar, Genovese, Mark, Derebail, Vimal, Rao, Panduranga, Chatham, Winn, Bubb, Michael, Lim, Sam, Hajian, Hooman, Gurtovaya, Oksana, Patel, Uptal, Tumlin, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Lupus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780527/
https://www.ncbi.nlm.nih.gov/pubmed/33380521
http://dx.doi.org/10.1136/rmdopen-2020-001490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780527/
https://www.ncbi.nlm.nih.gov/pubmed/33380521
http://dx.doi.org/10.1136/rmdopen-2020-001490

Ejemplares similares